Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Selectis Health (GBCS) Receivables (2017 - 2025)

Selectis Health's Receivables history spans 11 years, with the latest figure at $3.2 million for Q3 2025.

  • For Q3 2025, Receivables rose 67.73% year-over-year to $3.2 million; the TTM value through Sep 2025 reached $3.2 million, up 67.73%, while the annual FY2024 figure was $3.3 million, 14.32% up from the prior year.
  • Receivables for Q3 2025 was $3.2 million at Selectis Health, up from $3.0 million in the prior quarter.
  • Across five years, Receivables topped out at $4.4 million in Q3 2021 and bottomed at -$469302.0 in Q2 2022.
  • The 5-year median for Receivables is $2.9 million (2023), against an average of $2.8 million.
  • The largest annual shift saw Receivables plummeted 114.51% in 2022 before it soared 648.79% in 2023.
  • A 5-year view of Receivables shows it stood at $4.4 million in 2021, then decreased by 10.53% to $3.9 million in 2022, then dropped by 25.36% to $2.9 million in 2023, then grew by 14.32% to $3.3 million in 2024, then fell by 4.03% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for GBCS's Receivables are $3.2 million (Q3 2025), $3.0 million (Q2 2025), and $2.9 million (Q1 2025).